Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 10/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.64 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 3/20 | 0.59 |
| ▸ | PIK3C2G | O75747 | 3/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.59 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.51 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17465883 | 0.90 | DCLK1 (0.78) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL17465885 | 0.84 | DCLK1 (0.72) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL16065841 | 0.82 | DCLK1 (0.64) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL17465886 | 0.81 | LRRK2 (0.77) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL10098748 | 0.81 | LRRK2 (0.79) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL17519893 | 0.80 | DCLK1 (0.78) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL17721088 | 0.79 | DCLK1 (0.84) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL17465874 | 0.78 | NUAK1 (0.82) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL10098752 | 0.78 | DCLK1 (1.00) | DCLK1LRRK2MAPK7PIK3CDAURKA | |
| SCHEMBL30797848 | 0.78 | DCLK1 (1.00) | DCLK1LRRK2MAPK7PIK3CDAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885MAPK7 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.